Welcome to MolDiag-PaCa
The MolTools - DKFZ – IGB - MolDiagPaca Practical Course: Analysis and Interpretation of Complex Transcript Data took place at DKFZ in Heidelberg during the period Thursday, 14 December, to Saturday, 16 December 2006. In total 16 scientists of different European countries participated.

A large part of the course was hands-on data analysis. Due to the interests of the groups involved, most training was done on typical data produced from human cancer tissues and yeast. For overall data analyses as well as the identification of associations between transcriptional variations and annotated factors, including clinical information, GO-terms, mapping data and such alike, correspondence analysis was used extensively using the data warehouse M-Chips (Multi-Conditional Hybridisation Intensity Processing System).

In addition a public symposium with invited speakers from other institutions in Europe on Friday morning was organized. Speakers were Alvis Brazma (UK), Christine Steinhoff (Germany), Martin Kuiper (Belgium), Joaquin Dopazo (Spain), Eugene van Someren (The Netherlands), Stefan Winter (Germany) and Reinhard Guthke (Germany). They presented their views on various aspects of analysing transcriptional data.
The emphasis of the course, however, was in the actual hands-on dealing with data in order to get experience on the various parameters and settings possible.

>> Publications

Professor John Neoptolemos is Professor of Surgery, Head of the Division of Surgery and Oncology, and Head of School of Cancer Studies at the University of Liverpool. He leads one of the most successful clinical and academic surgical programmes in the United Kingdom. His specific areas of research are clinical trials of pancreatic cancer (including the large ESPAC trials as well as trials for advanced pancreatic cancer, e.g. Gemcap and Telovac); gene therapy, pre-symptomatic diagnosis and prognostic and biological predictors of treatment response to pancreatic cancer; hereditary and chronic pancreatitis and acute pancreatitis.

Role in Integrated Project: Coordinator of Work-package 7 (Clinical Trials).

Dr Bill Greenhalf is Lecturer in Molecular Biology in the Division of Surgery and Oncology at the University of Liverpool. He is the lead scientist on the EUROPAC registry. Bill has been involved in development of novel molecular screening approaches for pancreatic cancer for 10 years, it is apparent that these tests are still inadequate for screening the general public, but they are useful in high risk groups such as Familial Pancreatic Cancer ( FPC). Bill's group have identified that members of FPC families develop the disease at a younger age in each generation; as well as giving important clues about the nature of the disease, this allows a more accurate estimate of the risk an individual faces of developing cancer in the short term so we can treat the cancer as soon as possible. Similarly study of hereditary pancreatitis has allowed the link between pancreatitis and cancer to be put in a proper perspective, allowing more effective cancer screening of these patients.

Role in Integrated Project: Joint coordinator of Work-package 1 (Resources and Epidemiology).

Dr Eithne Costello's group is primarily focussed on analysis of proteins found in pancreatic cancer patients, but not in control groups. Her group analyses the protein profiles from microdissected tumour, and normal samples, blood and pancreatic juice. The underlying aim of all of these studies is to discover diagnostic and therapeutic targets that will ultimately benefit cancer patients.

Role in Integrated Project: Joint-coordinator and Chair of Work-package 4 (Proteomics).

Group members:

The Division of Surgery and Oncology,
5th Floor UCD Block,
Royal Liverpool University Hospital
Liverpool, UK
L34 3GA

Tel. +44 151 706 4170
Fax: +44 151 706 5826

Webpage: http://www.liv.ac.uk/surgery

Pancreatology (Karger Publishing)
Molecular Diagnosis of Pancreatic Cancer - Review Series

Exocrine pancreas cancer
The European Pancreatic
Cancer-Research Cooperative (EPC-RC)

Edited by T.M. Gress, J.P. Neoptolemos, N.R. Lemoine, F.X. Real

available for download free of charge

Press Release: "Pankreaskrebs rechtzeitig erkennen: Europäische Forscher entwickeln Molekulares Imaging" - "Early recognition of pancreatic cancer: European Scientists develop Molecular Imaging" (German only); Pressestelle, Ruhr-Uni-Bochum

Article: "Nur ein paar Zellen" - "Just a few cells" (German only); Rubin (autumn 2007). Scientific Magazine of Ruhr-Uni-Bochum.

Relevant publications from individual MolDiag-PaCa partners:

Prof. Dr. Jörg Rademann
Head of Medicinal Chemistry

Dr. Jens Peter von Kries
Head of Screening Unit

Research Profile
The group identifies and optimizes small molecules as specific biological effectors for studying protein structure, protein function and as potential starting points for pharmacological intervention. By doing so, the group enables the translation of biological knowledge gained in the areas of structure biology and cell biology into pharmacologically relevant small molecules.
For this purpose, we develop strategies in the areas of synthetic organic chemistry, library design, and bioassays. Most protein targets of the group are disease-related enzymes including proteases and phosphatases relevant to clinical indications including cancer, Alzheimer, tuberculosis, and SARS. Recently, the targeted proteins have been extended towards receptors and protein-protein interactions.
The FMP screening unit serves infrastructure for high to moderate throughput searches in screening libraries containing about 40.000 compounds. Supported screening technologies are based on fluorescence intensity, fluorescence polarization, luminescence and absorption measurements with different microplate readers using 384-well plates. Furthermore a new screening technology using an automated microscope for identification of compounds which affect cellular localisation of proteins in living cells will be established in 2007. The unit has set up and finished about 30 screening projects in the BMBF funded Mycobacterium tuberculosis consortium and supported about 10 guest projects since 2004.

Contribution to the Consortium
Identification and development of specific small molecules targeting pancreas-cancer related proteins as potential imaging probes for the early diagnosis of pancreas cancer.

Group members involved:
  • Sina Meyer
  • Christoph Erdmann
  • Marco Schmidt
  • Viviane Uryga-Polowy
  • Dr. Samuel Beligny

Prof. Dr. Jörg Rademann & Dr. Jens Peter von Kries
Leibniz-Insitut für Molekulare Pharmakologie, FMP
Robert-Rössle-Str. 10
13125 Berlin
This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it.